Analyst Ratings February 24, 2026

KBW raises Lemonade price target to $44, retains Underperform on execution concerns

Analyst lifts target after strong Q4 premiums and lower loss ratios but warns of competitive pressure and operational challenges

By Priya Menon LMND
KBW raises Lemonade price target to $44, retains Underperform on execution concerns
LMND

Keefe, Bruyette & Woods increased its price target on Lemonade Inc. to $44 from $40 following the insurer’s stronger-than-expected fourth-quarter results. Despite the higher target, the firm kept an Underperform rating, citing competition, potential AI disruption in personal lines, and the difficulty of sustaining rapid growth alongside low loss ratios and efficient customer acquisition.

Key Points

  • KBW raised its price target on Lemonade to $44 from $40 while keeping an Underperform rating.
  • The price-target increase follows Q4 2025 results that beat expectations due to prior-year development, with stronger premium growth and lower loss ratios noted.
  • Shares have been volatile, falling nearly 50% from a recent high and trading at $50.51; the stock remains up 45.6% over the past year and has a beta of 2.05.

Keefe, Bruyette & Woods raised its price target on Lemonade Inc. (NYSE:LMND) shares to $44 from $40 while maintaining an Underperform rating, the firm said in an update Monday. The upward revision in valuation followed the company’s fourth-quarter 2025 results, which outpaced expectations largely due to prior-year development.

Reasoning behind the change

KBW said it adjusted its forecasts to reflect stronger premium growth and lower loss ratios reported in the quarter, though those positives were partly offset by higher operating expenses. The firm also set its first-quarter 2026 estimate slightly below Lemonade’s own guidance to allow for potential damages stemming from ongoing Northeast winter storms.

Stock movement and market context

Shares of Lemonade have suffered a marked pullback from recent highs. The stock fell almost 50% from a peak of $99.90 recorded a month ago and was trading at $50.51 at the time of the note. The decline has accelerated in the short term, with a 21.8% drop over the past week alone and a 29% fall year-to-date. Despite that volatility, the share price still reflects a 45.6% gain over the past 12 months. KBW also highlighted the stock’s elevated beta of 2.05.

The firm referenced analysis from InvestingPro that indicates the stock may be undervalued at current levels, with that platform’s Fair Value suggesting upside potential.

Outlook and analyst concerns

KBW retained its Underperform stance because it expects downside risk versus consensus forecasts for 2027. The analyst team pointed to several structural concerns, including the potential for AI-driven disruption in personal lines insurance and increasing competition in the insurtech space.

KBW warned that delivering 30% plus growth while maintaining persistently low loss ratios and continuing to acquire customers efficiently may prove difficult at the same time, particularly as competitive pressure intensifies. Those execution risks underpin the firm’s caution despite the recent operational beats.

Quarterly results

Lemonade reported fourth-quarter 2025 results that topped analyst expectations on both the bottom line and revenue. The company recorded earnings per share of negative $0.29, beating the forecasted negative $0.39, which the firm characterized as a 25.64% positive surprise. Revenue for the quarter was $228 million, above the anticipated $216.26 million, representing a 5.43% surprise.

Those results signaled a stronger-than-expected performance for the period and were noted as a positive data point for investors. The company’s showing has drawn attention from financial analysts, although KBW’s note stated that specific upgrades or downgrades from other analysts were not detailed in its commentary.

Implications for investors

KBW’s decision to lift its price target despite keeping an Underperform rating illustrates a mixed view: recognition of recent operational improvement balanced against medium-term execution and competitive risks. The firm’s modestly conservative early-2026 estimate to reflect possible storm-related claims is an example of the near-term uncertainty that analysts are factoring into models.

Investors watching Lemonade should weigh the company’s ability to sustain premium expansion and low loss ratios against rising operating costs and the competitive dynamics in personal lines insurance highlighted by KBW.

Risks

  • Sustaining 30% plus growth while maintaining low loss ratios and efficient customer acquisition may be difficult amid rising competition - impacts insurtech and personal lines insurance sectors.
  • Potential damages from ongoing Northeast winter storms could affect near-term results, prompting conservative Q1 2026 estimates - impacts property and casualty insurance results.
  • AI-driven disruption and intensifying competition in personal lines insurance could pressure margins and growth, contributing to downside risk to 2027 consensus estimates - impacts broader insurance and financial markets.

More from Analyst Ratings

Freedom Capital nudges up MDU Resources target as utility businesses drive gains Feb 24, 2026 BofA Maintains Buy on Eli Lilly, Sees Little U.S. GLP-1 Impact from Novo Price Move Feb 24, 2026 Benchmark Lifts SGHC Price Target After Fiscal 2025 Beat; Buy Rating Reiterated Feb 24, 2026 Benchmark Lifts Zoom Price Target to $115, Cites AI Strategy and Strong Fundamentals Feb 24, 2026 Benchmark Upholds Buy Rating on Diamondback After Mixed Q4 Results Feb 24, 2026